P. Dias Wickramanayake

562 total citations
22 papers, 400 citations indexed

About

P. Dias Wickramanayake is a scholar working on Pathology and Forensic Medicine, Hematology and Oncology. According to data from OpenAlex, P. Dias Wickramanayake has authored 22 papers receiving a total of 400 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pathology and Forensic Medicine, 6 papers in Hematology and 5 papers in Oncology. Recurrent topics in P. Dias Wickramanayake's work include Acute Myeloid Leukemia Research (6 papers), Lymphoma Diagnosis and Treatment (5 papers) and Chronic Lymphocytic Leukemia Research (3 papers). P. Dias Wickramanayake is often cited by papers focused on Acute Myeloid Leukemia Research (6 papers), Lymphoma Diagnosis and Treatment (5 papers) and Chronic Lymphocytic Leukemia Research (3 papers). P. Dias Wickramanayake collaborates with scholars based in Germany and United States. P. Dias Wickramanayake's co-authors include Volker Diehl, Hans Tesch, H. O. Klein, Andreas Engert, Markus Loeffler, Andreas Josting, Giuseppe Lentini, Bettina Hentschel, N Brock and Jan Pohl and has published in prestigious journals such as American Journal of Clinical Nutrition, Cancer and Annals of Oncology.

In The Last Decade

P. Dias Wickramanayake

20 papers receiving 378 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
P. Dias Wickramanayake Germany 10 165 160 149 84 76 22 400
Yoshimi Ishii Japan 12 150 0.9× 89 0.6× 133 0.9× 54 0.6× 45 0.6× 43 339
Grant McQuaker United Kingdom 11 172 1.0× 319 2.0× 187 1.3× 144 1.7× 25 0.3× 21 548
R S Stein United States 9 233 1.4× 341 2.1× 196 1.3× 226 2.7× 45 0.6× 9 624
Bodey Gp United States 8 189 1.1× 104 0.7× 163 1.1× 121 1.4× 51 0.7× 10 380
Moira Lucesole Italy 8 122 0.7× 219 1.4× 153 1.0× 85 1.0× 38 0.5× 11 373
Debra Frei‐Lahr United States 9 36 0.2× 192 1.2× 128 0.9× 88 1.0× 111 1.5× 18 487
Beata Stella‐Hołowiecka Poland 9 134 0.8× 213 1.3× 69 0.5× 195 2.3× 58 0.8× 31 440
MC Poon Canada 13 36 0.2× 362 2.3× 88 0.6× 129 1.5× 62 0.8× 26 482
Uta Brunnberg Germany 10 120 0.7× 94 0.6× 133 0.9× 61 0.7× 29 0.4× 23 345
Laurent Pascal France 9 83 0.5× 272 1.7× 136 0.9× 195 2.3× 15 0.2× 25 438

Countries citing papers authored by P. Dias Wickramanayake

Since Specialization
Citations

This map shows the geographic impact of P. Dias Wickramanayake's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Dias Wickramanayake with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Dias Wickramanayake more than expected).

Fields of papers citing papers by P. Dias Wickramanayake

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Dias Wickramanayake. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Dias Wickramanayake. The network helps show where P. Dias Wickramanayake may publish in the future.

Co-authorship network of co-authors of P. Dias Wickramanayake

This figure shows the co-authorship network connecting the top 25 collaborators of P. Dias Wickramanayake. A scholar is included among the top collaborators of P. Dias Wickramanayake based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Dias Wickramanayake. P. Dias Wickramanayake is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Klein, H. O., et al.. (2008). Chemotherapieprotokoll zur Behandlung des metastasierenden Magenkarzinoms: Methotrexat, Adriamycin und 5-Fluorouracil. DMW - Deutsche Medizinische Wochenschrift. 107(45). 1708–1712.
2.
Wickramanayake, P. Dias, et al.. (2008). Chemotherapieprotokoll für das metastasierende kolorektale Karzinom: Methotrexat, 5-Fluorouracil und Cytarabin. DMW - Deutsche Medizinische Wochenschrift. 110(13). 487–491.
3.
4.
Lentini, Giuseppe, Bettina Hentschel, P. Dias Wickramanayake, et al.. (2000). Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony‐stimulating factor and erythropoietin. British Journal of Haematology. 109(2). 367–375. 75 indexed citations
5.
Josting, Andreas, Marcel Reiser, P. Dias Wickramanayake, et al.. (2000). Brief Report Dexa-BEAM: An Effective Regimen for Cytoreduction Prior to High-Dose Chemotherapy with Autologous Stem Cell Support for Patients with Relapsed/Refractory Mantle-Cell Lymphema. Leukemia & lymphoma. 37(1-2). 185–187. 9 indexed citations
6.
Staib, Peter, Axel Glasmacher, Achim Neufang, et al.. (1999). Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML. Annals of Hematology. 78(9). 418–425. 55 indexed citations
7.
Reiser, Marcel, Andreas Josting, P. Dias Wickramanayake, et al.. (1999). Dexa-BEAM is not Effective in Patients with Relapsed or Resistant Aggressive High-Grade Non-Hodgkin's Lymphoma. Leukemia & lymphoma. 33(3-4). 305–312. 13 indexed citations
8.
9.
Staib, Peter, B. Lathan, Hans Tesch, et al.. (1998). Cytosine arabinoside, etoposide and aclarubicin (AVA) for the treatment of acute myeloid leukemia (AML) in elderly patients. Annals of Oncology. 9(2). 221–223. 6 indexed citations
10.
Lentini, Giuseppe, Hans Tesch, Bettina Hentschel, et al.. (1997). 158 Long term treatment of intermediate risk myelodys-plastic syndrome with rhG-CSF and rhEPO: Interim report of an ongoing randomized phase III trial. Leukemia Research. 21(1). S41–S41. 1 indexed citations
11.
Plum, Georg, Christof Scheid, Caspar Franzen, et al.. (1996). Empirical Liposomal Amphotericin-B Therapy in a Neutropenic Patient: Breakthrough of Disseminated Blastoschizomyces capitatus Infection. Zentralblatt für Bakteriologie. 284(2-3). 361–366. 11 indexed citations
12.
Schwonzen, Martin, Christoph Pohl, T. Steinmetz, et al.. (1992). Bone marrow involvement in non‐Hodgkin's lymphoma: increased diagnostic sensitivity by combination of immunocytology, cytomorphology and trephine histology. British Journal of Haematology. 81(3). 362–369. 10 indexed citations
13.
Wickramanayake, P. Dias, et al.. (1991). [Myelodysplastic syndrome (preleukemia)].. PubMed. 86(3). 157–64. 4 indexed citations
14.
Wickramanayake, P. Dias, et al.. (1989). Nutrient intake and nitrogen metabolism in cancer patients during oncological chemotherapy. American Journal of Clinical Nutrition. 50(3). 454–459. 13 indexed citations
15.
Klein, H. O., et al.. (1986). 5-Fluorouracil, adriamycin, and methotrexat — A combination protocol (fameth) for treatment of metastasized stomach cancer. Journal of Cancer Research and Clinical Oncology. 111(S1). S86–S86. 2 indexed citations
16.
Wickramanayake, P. Dias & H. O. Klein. (1986). Enhanced incorporation of 5-fluorouracil (5-FU) into DNA of a human colon carcinoma after pretreatment with methotrexate (MTX). Journal of Cancer Research and Clinical Oncology. 111(S1). S93–S93. 1 indexed citations
17.
Wickramanayake, P. Dias, Markus Loeffler, H. O. Klein, W Groth, & H. E. Wichmann. (1985). Growth dependent cell proliferation kinetics of a human malignant melanoma grown in nude mice. Journal of Cancer Research and Clinical Oncology. 110(1). 11–16. 4 indexed citations
18.
Wickramanayake, P. Dias, et al.. (1984). Preclinical evaluation of toxicity and therapeutic efficacy of a stabilized cytostatic metabolite of cyclophosphamide (ASTA Z 7557, INN mafosfamide). Investigational New Drugs. 2(2). 191–199. 2 indexed citations
19.
20.
Klein, H. O., et al.. (1983). High-dose ifosfamide and mesna as continuous infusion over five days—a phase I/II trial. Cancer Treatment Reviews. 10. 167–173. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yoshimi Ishii Breakdown of academic impact, for papers by Grant McQuaker Breakdown of academic impact, for papers by R S Stein Breakdown of academic impact, for papers by Bodey Gp Breakdown of academic impact, for papers by Moira Lucesole Breakdown of academic impact, for papers by Debra Frei‐Lahr Breakdown of academic impact, for papers by Beata Stella‐Hołowiecka Breakdown of academic impact, for papers by MC Poon Breakdown of academic impact, for papers by Uta Brunnberg Breakdown of academic impact, for papers by Laurent Pascal
Rankless by CCL
2026